Top Healthcare Equipment Companies To Own For 2014

RadioShack (RSH) has done enough to take the electronics industry to a new level with various turnarounds in its history. But it is struggling to remain competitive in the market as it has lost nearly 85% of its value since the beginning of 2010.

RadioShack posted a worse-than-expected loss recently, and ratings agency Standard & Poor�� warned that the company could default on its debt within a year. In such circumstances, the company is looking for a turnaround with its transformational strategies.

A Turnaround Plan

The company is planning to renovate its stores with new displays that could bring back consumers, but is it enough to woo its shareholders who are aware of the challenges? Moreover, RadioShack is facing a fundamental problem that could even pressure the company to exit from the market.

Though the company reported 1.3% increase in same-store sales, it was accompanied by an operating loss of $41 million ��about 300% increase from the previous year. Also, the prior two quarters had witnessed a drop of same-store sales of 5.7% and 5%, respectively.

Top 10 Safest Stocks To Own For 2015: Muenchener Rueckversicherungs Gesellschaft AG in Muenchen (MUV2)

Muenchener Rueckversicherungs Gesellschaft AG in Muenchen is a Germany-based holding company engaged in reinsurance and insurance business fields. The Company diversifies its operations into reinsurance, primary insurance, Munich Health and Asset management. The Reinsurance business comprises five divisions: Life; Europe and Latin America; Germany, Asia Pacific and Africa; Special and Financial Risks, and Global Clients and North America. The business covers a range of products from traditional reinsurance products to solutions for risk assumption. The Company's primary insurance activities are combined into the ERGO Insurance Group (ERGO) and offers direct insurance, life, property-casualty, health, legal expenses and travel insurance products. It covers the Company's international health reinsurance business and health primary insurance outside Germany and engages the risk management services. The Asset management business handles the investment activities of Munich Re and ERGO. Advisors' Opinion:

• [By Jonathan Morgan]

  Munich Re (MUV2), the world�� biggest reinsurer, dropped 4.9 percent to 145.25 euros after it said second-quarter profit fell 35 percent, missing analysts��estimates, as claims arising from natural disasters rose. Net income dropped to 529 million euros from 808 million euros a year earlier, trailing the 557.1 million-euro average estimate of analysts surveyed by Bloomberg.

Top Healthcare Equipment Companies To Own For 2014: Zinco Do Brasil Inc (ZNBR)

Zinco do Brasil Inc., formerly TurkPower Corporation, incorporated on November 4, 2004, has been a Turkish-American consulting and service operations firm and junior mining company. TurkPower offered its domestic and international clients consulting services and plans to act as a full service operator for wind, hydro, solar, coal and geothermal energy parks in Turkey.

In November 2011, the Company ceased all operations in Turkey. During the fiscal year ended May 31, 2012 (fiscal 2012) the Company impaired its entire mining company investment.

Advisors' Opinion:

• [By Peter Graham]

  Small cap mining stocks Discovery Minerals Ltd (OTCMKTS: DSCR), Zinco Do Brasil Inc (OTCMKTS: ZNBR) and Amalgamated Gold and Silver Inc (OTCMKTS: BCHS) have been getting some extra attention lately as one stock surged last Friday while the other two are or have been in the past, the subject of paid promotions. It goes without saying though that small cap mining stocks tend to be riskier than your average stock. But do these three small cap mining stocks have what it takes to produce a mother lode for investors? Here is a deeper dig into all three:

Top Healthcare Equipment Companies To Own For 2014: China Jo-Jo Drugstores Inc.(CJJD)

China Jo-Jo Drugstores, Inc. owns and operates a retail pharmacy chain in the People?s Republic of China. Its stores sell various medicinal products, including prescription and over-the-counter drugs, nutritional supplements, traditional Chinese medicine products, personal care products, family care products, and medical devices, as well as convenience products including consumable, seasonal, and promotional items. The company also has licensed doctors, who provide consultation, examination, and treatment of common ailments. In addition, its stores include medical clinics that offer urgent care, traditional Chinese medicines, and minor outpatient surgical treatments. The company operates a chain of approximately 55 drugstores under the Jiuzhou Grand Pharmacy Quannuo Grand Pharmacy, and Lydia Grand Pharmacy brand names. The company is headquartered in Hangzhou, the People?s Republic of China.

Advisors' Opinion:

• [By Roberto Pedone]

   

   

  Another under-$10 drug retailer that's starting to move within range of triggering a big breakout trade is China Jo-Jo Drugstores (CJJD), which operates as a retailer and distributor of pharmaceutical and other health care products in the People's Republic of China. This stock has been on fire for the last three months, with shares ripping higher by 46%.

  If you take a look at the chart for China Jo-Jo Drugstores you'll notice that this stock has been uptrending strong over the last month and change, with shares moving higher from its low of 65 cents per share to its recent high of $1.18 a share. During that uptrend, shares of CJJD have been making mostly higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of CJJD within range of triggering a big breakout trade above some near-term and past overhead resistance levels.

  Market players should now look for long-biased trades in CJJD if it manages to break out above some near-term overhead resistance at $1.18 a share and then once it clears some past overhead resistance levels at $1.21 to $1.32 a share high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 99,122 shares. If that breakout hits soon, then CJJD will set up to re-test or possibly take out its next major overhead resistance levels at $1.70 to its 52-week high at $1.99 a share.

  Traders can look to buy CJJD off weakness to anticipate that breakout and simply use a stop that sits just below its 50-day moving average of 98 cents per share. One can also buy CJJD off strength once it starts to clear those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Top Healthcare Equipment Companies To Own For 2014: Cell Therapeutics Inc (CTIC)

Cell Therapeutics, Inc. (CTI), incorporated in 1991, develops, acquires and commercializes treatments for cancer. The Company�� research, development, acquisition and in-licensing activities concentrate on identifying and developing new ways to treat cancer. As of December 31, 2011, CTI focused its efforts on Pixuvri (pixantrone dimaleate) (Pixuvri), OPAXIO (paclitaxel poliglumex) (OPAXIO), tosedostat, brostallicin and bisplatinates. As of December 31, 2011, it developed Pixuvri, an anthracycline derivative for the treatment of hematologic malignancies and solid tumors. Another late-stage drug candidate of the Company, OPAXIO, is being studied as a potential maintenance therapy for women with advanced stage ovarian cancer, who achieve a complete remission following first-line therapy with paclitaxel and carboplatin. As of December 31, 2011, it also developed tosedostat in collaboration with Chroma Therapeutics, Ltd. (Chroma). On May 31, 2012, CTI completed its acquisition gaining worldwide rights to S*BIO Pte Ltd.'s (S*BIO) pacritinib.

Pixuvri

As of December 31, 2011, the Company developed Pixuvri, an aza-anthracenedione derivative, for the treatment of non-Hodgkin�� lymphoma (NHL), and various other hematologic malignancies, and solid tumors. Pixuvri was studied in the Company�� EXTEND, or PIX301, clinical trial, which was a phase III single-agent trial of Pixuvri for patients with relapsed, refractory aggressive NHL who received two or more prior therapies and who were sensitive to treatment with anthracyclines. On September 28, 2011, CTI announced that a second independent radiology assessment of response and progression endpoint data from its PIX301 clinical trial of Pixuvri was achieved with statistical significance. The results of the EXTEND trial met its primary endpoint and showed that patients randomized to treatment with Pixuvri achieved a significantly higher rate of confirmed and unconfirmed complete response compared to patients treated with standard chem! otherapy had a significantly increased overall response rate and experienced a statistically significant improvement in median progression free survival. Pixuvri had predictable and manageable toxicities when administered at the proposed dose and schedule in the EXTEND clinical trial in heavily pre-treated patients. In March 2011, the Company initiated the PIX-R trial to study Pixuvri in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Pixuvri has also been studied in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens. In the second quarter of 2010, the NCCTG opened this phase II study for enrollment. The study is closed to accrual and results are expected to be reported by the NCCTG later in 2012.

OPAXIO

OPAXIO is the Company�� biologically-enhanced chemotherapeutic agent that links paclitaxel to a biodegradable polyglutamate polymer, resulting in a new chemical entity. As of December 31, 2011, the Company focused its development of OPAXIO on ovarian, brain, esophageal, head and neck cancer. OPAXIO was designed to improve the delivery of paclitaxel to tumor tissue while protecting normal tissue from toxic side effects. In November 2010, results were presented by the Brown University Oncology Group from a phase II trial of OPAXIO combined with temozolomide (TMZ), and radiotherapy in patients with newly-diagnosed, high-grade gliomas, a type of brain cancer. The trial demonstrated a high rate of complete and partial responses and a high rate of six month progression free survival (PFS). Based on these results, the Brown University Oncology Group has initiated a randomized, multicenter, phase II study of OPAXIO and standard radiotherapy versus TMZ and radiotherapy for newly diagnosed patients with glioblastoma with an active gene termed MGMT that reduces responsiveness to TMZ. A phase I/II study of OPAXIO combined with radi! otherapy ! and cisplatin was initiated by SUNY Upstate Medical University, in patients with locally advanced head and neck cancer.

Tosedostat

In March 2011, the Company entered into a co-development and license agreement with Chroma Therapeutics, Ltd. (Chroma), providing the Company with marketing and co-development rights to Chroma�� drug candidate, tosedostat, in North, Central and South America. Tosedostat is an oral, aminopeptidase inhibitor that has demonstrated anti-tumor responses in blood related cancers and solid tumors in phase I-II clinical trials. Interim results from the phase II OPAL study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) showed that once-daily, oral doses of tosedostat had predictable and manageable toxicities and results demonstrated response rates, including a high-response rate among patients who received prior hypomethylating agents, which are used to treat myelodysplastic syndrome (MDS), a precursor of AML.

Brostallicin

As of December 31, 2011, the Company developed brostallicin through its wholly owned subsidiary, Systems Medicine LLC, which holds rights to use, develop, import and export brostallicin. Brostallicin is a synthetic deoxyribonucleic acid (DNA) minor groove binding agent that has demonstrated anti-tumor activity and a favorable safety profile in clinical trials, in which more than 230 patients have been treated as of December 31, 2011. The Company uses a genomic-based platform to guide the development of brostallicin. A phase II study of brostallicin in relapsed, refractory soft tissue sarcoma met its predefined activity and safety hurdles and resulted in a first-line phase II clinical trial study that was conducted by the European Organization for Research and Treatment of Cancer (EORTC).

The Company competes with Bristol-Myers Squibb Company, Sanofi-Aventis, Pfizer, Roche Group, Genentech, Inc., Astellas Pharma, Eli Lilly and Company, Celgene, Telik, I! nc., TEVA! Pharmaceuticals Industries Ltd. and PharmaMar.

Advisors' Opinion:

• [By Bryan Murphy]

  If you're reading this, then odds are you already know that the last two weeks (not even a full two weeks) have been more fruitful for Cell Therapeutics Inc. (NASDAQ:CTIC) shareholders than the prior two years have been - the stock's up 28% since last Thursday. And, odds are you already know why. The question most of you are asking now is, can CTIC actually keep climbing at this pace, or even keep climbing at any pace? The answer is "yes", though floating that answer almost inherently requires a deeper explanation.

• [By John Udovich]

  Large and small cap cancer stocks Gilead Sciences, Inc (NASDAQ: GILD), Celgene Corporation (NASDAQ: CELG), Veracyte (NASDAQ: VCYT), Genomic Health, Inc (NASDAQ: GHDX), Cell Therapeutics Inc (NASDAQ: CTIC) and MetaStat Inc (OTCMKTS: MTST) have all been producing a steady stream of news lately for biotech investors looking for a way to cash in on the growth in development of�cancer treatments. Just consider the following news:

• [By Sean Williams]

  Cell Therapeutics (NASDAQ: CTIC  )
  Certainly no discussion of companies with large accumulated deficits would be complete without discussing a biotechnology company. It's perfectly understandable to see a biotech, especially a clinical-stage one, run with an accumulated deficit, as it takes time and money to build up a drug pipeline. However, after multiple complete response letters (the equivalent of a rejection) by the Food and Drug Administration and years without an approved drug, Cell Therapeutics racked up an astounding $1.83 billion in accumulated deficits through the end of fiscal 2012. By comparison, that's nearly 56 times larger than its shareholder equity.�

• [By John Udovich]

  If you have not been watching the biotech sector lately, you should start paying attention as the sector along with small cap biotech stocks like Cell Therapeutics Inc (NASDAQ: CTIC), BIND Therapeutics Inc (NASDAQ: BIND) and TNI BioTech (OTCMKTS: TNIB) continue to produce a steady stream of good news for investors thanks to positive industry trends. Moreover, Ophthotech Corp (NASDAQ: OPHT), Foundation Medicine Inc (NASDAQ: FMI), Evoke Pharma and Fate Therapeutics Inc (NASDAQ: FATE) are this week's biotech IPOs that will no doubt be watched closely by Wall Street and industry observers in general. With that in mind, consider the following biotech news or recent articles about the industry and the small cap players in it:

Top Healthcare Equipment Companies To Own For 2014: Orange SA (ORAN)

Orange SA, formerly France Telecom S.A., incorporated on December 31, 1996, is an European mobile operator, an asymmetric digital subscriber line (ADSL) Internet access provider in Europe, and telecommunications services provider for multinational businesses under the Orange Business Services brand. As of December 31, 2010, France Telecom provided services to 209 million customers, of which 150 million were mobile phone customers and 13.7 million were broadband Internet customers, and as of June 30, 2011, provided services to 217.3 million customers. It offers its individual customers, businesses and other telecommunications operators a line of services covering fixed and mobile communications, data transmission, the Internet and multimedia, and other services. The Company�� segments include France, Poland, Spain, Rest of the World, Business Communication Services, International Carriers and Shared Services.

France

The range of services in the Home segment in France is made up of fixed-line telephony services; other consumer services; online, Internet access, and multimedia services; advertising-management and Internet portal business; content-related business, and carrier services. France Telecom�� traditional fixed-line telephony services provide access to the network, local and long-distance telephone communication services throughout France, and international calls. In addition, France Telecom offers its fixed-line telephony subscribers a broad range of value-added services. The France Telecom Group has a number of portals, including Orange.fr, which is either Web- or mobile-accessible. In December 2010, its audience reached 22.5 million, and Voila.fr and Cityvox (entertainment and leisure listing site in France) in its different formats, such as Cityvox.fr, Cinefil.com, Spectacles.fr, Concert.fr and WebCity.fr. The primary revenue source is online advertising sold by the Orange Advertising Network. This advertising management department sells advertising space for ab! out 20 third-party sites, both Web and mobile.

Orange�� offers are built around three product lines: postpaid, prepaid and convergent offers. Orange offers two categories of prepaid offer, to which calls are charged by the second from the first second: The Mobicarte, includes a range of recharges from 5 to 100 euros and Orange Initial, which enables the customer to be billed monthly depending on his or her actual consumption. Orange also has a number of offers that pair mobile use and mobile Internet access with all-in-one offers, including both the hardware and an Internet access plan. The USB 3G+ plans enable connection to the Internet via the mobile broadband network or the Orange public wireless fidelity (WiFi) network from a laptop computer, multimedia mobile phone or a tablet personal computer.

The Company competes with SFR-Neuf Cegetel, Free, Bouygues Telecom, Numericable, Google and Voila.

Poland

Orange (the brand under which the TP Group subsidiary, PTK Centertel trades) had a total of 14.3 million during the year ended December 31, 2010. In April 2010, PTK Centertel introduced segmented postpaid offers for residential customers. Depending on the usage profile, customers can choose from three types of tariff plans: Dolphin tariffs for frequent users of voice services, Pelican for customers focused on text and community Web-services, and Panther for users of mobile data services (Internet, email). The mobile broadband Internet customer base (Edge and 3G data services) reached 547,000 customers during 2010. In 2010, Orange introduced a SIM-only mobile Internet offer and a portfolio of terminals dedicated to the Orange Free offer.

The Company competes with Netia, Multimedia Polska, Aster and Hyperion.

Spain

Orange Espana, operating under Orange, Ya.com and OBS (Enterprise) brands offers fixed and mobile telecommunication services to more than 13 million customers in the residential, professional, business and who! lesale se! gments. Orange Espana�� physical distribution network consists in 2,922 points of presence, including Orange own shops, franchises, specialized shops under the Orange brand, non exclusive specialized shops, and a network of retailers. Orange Espana also distributes its services through distance selling channels, and its own online portal. Orange Espana fixed access infrastructure, based on its own optic fiber network and ADSL roll-out, enables delivery of advanced telecommunication services, including broadband Internet access, voice over Internet protocol (VoIP), internet protocol television (IPTV), television (TV) streaming, video on demand (VOD) and advanced business services.

The Company competes with Telefonica, ONO, Vodafone and Jazztel.

Rest of the world

The France Telecom Group is present in Luxembourg via Orange S.A. (formerly VOXmobile), a wholly owned subsidiary of Mobistar. The Luxembourg subsidiary, VOXmobile, was renamed Orange S.A. in October 2009. During the year ended December 31, 2010, Orange S.A. had 88,900 active mobile telephony customers.

The Company competes with Proximus, Mobistar, Base, ex-Mobifon, Telefonica O2, Deutsche Telekom, Swisscom, Sunrise, Moldtelecom, Starnet, ECMS, Vodafone Egypt and Etisalat U.A.E.

Enterprise Communications Services

The Orange Business Services brand covers both the Enterprise Communication Services (ECS) unit, which supplies communications services to multinational companies and corporate accounts and small and medium enterprises (SMEs) in France and Orange subsidiaries Business-to-Business (B2B) activities.

Orange Business Services covers the Company�� business customers in more than 160 countries and regions where it provides local technical and commercial assistance. This business segment includes a number of subsidiaries, including Etrali (trading solutions), Almerys (health), Orange Consulting (project management, telecom consulting), Multimedia Business Se! rvices (m! ultimedia contact centers), Neocles (virtualization solutions), IT&Labs (design and development of embedded Machine-to-Machine applications, vehicle fleet management), Obiane and Telecom System (secure network integration), Alsy (integration services), EGT (equipment and services for video conferences), and GlobeCast (multimedia broadcast systems).

The Company competes with IBM, HP, Microsoft and Cisco.

The Company competes with COLT Telecom, Numericable-Completel, BT Global Services, AT&T Business Services, Verizon Business, T-Systems, Reliance Globalcom, Tata Communications, Belgacom Group, NextiraOne, Spie Communication, NTT Group, IBM Global Services, HP Enterprise Services, Atos Origin, Salesforce and Amazon.

International Carriers and Shared Services

Orange�� International Carriers activity is based on long-distance network infrastructure and offers a range of solutions on the international market. The Company is involved in the design, construction and operation of submarine cables. The Company�� wholesale activity includes a worldwide network with over 120 presence points and 130,000 kilometers of fiber optic cable; a worldwide network of Internet protocol (IP) routes with end users in over 220 countries and connections to over 250 Internet service providers and a hit rate of over 85% for all European net surfers. France Telecom�� network has over 330 direct routes and interconnections with over 359 operators, and coverage in over 900 destinations with around-the-clock technical support. Its range of solutions includes interconnection, interoperability and signaling solutions for messaging, voice and video telephony services and the Orange Roaming Hub (Global eXchange) solution for moving from a bilateral model to a multilateral roaming system.

France Telecom has developed activities related to its core business line, such as content broadcasting, audience and advertising, and also healthcare activities. Orange offers free a! nd paying! content on its own channels, paid program packages, Video On Demand, music and game offers. Orange distributes content provided by third parties (television, games, music) on fixed-line and mobile networks both inside and outside France. Orange also produces its own channels: Orange Sport and Orange Cinema�� five different channels. Studio 37, is a subsidiary for investing in cinematographic rights, through both co-production and the acquisition of catalogue rights. During the year ended December 32, 2010, Studio 37 supported the launch of 15 films, including the Gainsbourg and Fatal. The Viaccess group, a France Telecom subsidiary, offers access solutions to television content. Orange is present in the games market through the games it sells on the orange.fr portal (Casual Games dedicated to family type games, such as breakout clones or riddles). Orange Healthcare, is the Company�� healthcare division, focused on developing service packages for the whole sector within a partnership approach.

The Company competes with Telefonica, Deutsche Telekom, Telia Sonera and AT&T.

Advisors' Opinion:

• [By Patricio Kehoe] rance, the company has expanded its services onto 32 other countries, serving a total of 236 million customers. Hence, it has become one of the world�� largest telecommunications carriers and the third largest wireless operator in Europe.

  The firm provides local phone, domestic and international long distance, wireless data communications, Internet access, multimedia, broadcast and cable TV services. Its business arm, Orange Business Services, accounts for 15.9% of the company�� sales and is one of the leading providers of communications services to multinational companies.

  A Healthy Management

  In order to counter the aggressive pricing strategy from wireless new entrant Iliad SA (ILD) in France, Orange was forced to reduce prices. Thus, the firm has continued to add wireless subscribers but at a lower average revenue per user, mainly through its low-end Sosh brand.

  Further, its existing contract base keeps rolling into lower priced plans. As a result, the company�� revenue has plunged, in spite of which the firm has managed to improve its bottom line year over year in 2013.

  Management�� efficiency is also evidenced by its decision to reduce its non-core assets in order to concentrate on its most profitable businesses. Consequently, almost nine months after its initial tender, Orange divested its Dominican unit to Luxemburg-based Altice SA (ATC) for $1.4 billion last week.

  The news boosted its stock price, which climbed 2.31% on the NYSE last Wednesday. This operation provides the company with significant cash volume to reduce its debt burden and invest in Europe and other emerging markets.

  Growth Drivers

  The company is accelerating infrastructural developments to drive 4G LTE expansion in order to support wireless growth in France and other key regions across Europe. In 2013, it captured 40% of the French population with 4,200 sites and it also reached 0.5 million customers and 30% of its network cover

• [By Chandan Dubey]

  I have been holding shares of Orange (ORAN)(XPAR:ORA), previously known as France Telecom, since December 2011. In this article, I want to discuss some of the things that worry me about the company.

• [By Sean Williams]

  Also in the news ...
  Let's not sugarcoat this one iota: It was a really busy week for earnings news, with network equipment maker QLogic (NASDAQ: QLGC  ) , printing and IT specialist Xerox (NYSE: XRX  ) , and telecommunication services provider Orange (NYSE: ORAN  ) all reporting results.

Top Healthcare Equipment Companies To Own For 2014: Bristow Group Inc (BRS)

Bristow Group Inc., together with its subsidiaries, provides helicopter services to the offshore energy industry primarily in Europe, West Africa, North America, Australia, and internationally. Its helicopters are used principally to transport personnel between onshore bases and offshore platforms, drilling rigs, and installations, as well as to transport time-sensitive equipment to offshore locations. The company also offers helicopter flight training services to commercial pilots and flight instructors through its Bristow Academy with facilities in Titusville, Florida; Concord, California; New Iberia, Louisiana and Gloucestershire, England. In addition, it provides military training; and helicopter repair, engineering support, aircraft leasing, airport management, and search and rescue services. Bristow Group provides its helicopter services to integrated, national, and independent oil and gas companies. As of March 31, 2011, it operated a fleet of 569 aircraft. The comp any was founded in 1969 and is based in Houston, Texas.

Advisors' Opinion:

• [By GURUFOCUS]

  First comes Bristow Group Inc. (BRS), which provides helicopter services to offshore energy rigs, and is a holding in our traditional mid-cap, small-to-mid cap, and small-cap portfolios. Although energy exploration and production can clearly fluctuate, Bristow offsets those shifts through long-term contracts lasting roughly three to five years. Furthermore, Bristow receives ��onthly standing charges���meaning it gets paid whether its helicopters fly or not��mounting to 70% of its operating income.

• [By J. Royden Ward]

  Based in Houston and founded in 1969, Bristow Group (BRS) has major transportation operations in the US Gulf of Mexico and the North Sea.

  Bristow also operates in most of the other major offshore oil and gas producing regions of the world, including Alaska, Australia, Brazil, Mexico, Nigeria, Russia, and Trinidad.

• [By Seth Jayson]

  Bristow Group (NYSE: BRS  ) reported earnings on May 22. Here are the numbers you need to know.

  The 10-second takeaway
  For the quarter ended March 31 (Q4), Bristow Group beat expectations on revenues and met expectations on earnings per share.